Skip to main content
Clinical Trials/NCT04255043
NCT04255043
Completed
Not Applicable

Intravascular Ultrasound Versus Angiography Guided Drug-coated Balloon Treatment for Denovo Lesions in High Bleeding Risk Patients: a Prospective, Multi-center, Randomized Controlled Trial

Nanjing First Hospital, Nanjing Medical University1 site in 1 country260 target enrollmentFebruary 3, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
Nanjing First Hospital, Nanjing Medical University
Enrollment
260
Locations
1
Primary Endpoint
late lumen loss (LLL) at 7 months after procedure
Status
Completed
Last Updated
last year

Overview

Brief Summary

Drug-coated balloon (DCB) is an alternative choice for denovo lesions in coronary artery disease patients with high bleeding risk. Intravascular ultrasound (IVUS) can provide more details of coronary anatomy and stent implantation, overcoming a number of limitations of coronary angiography. However, the benefit of IVUS-guided DCB treatment has not been investigated. This study is designed to compare IVUS-guided and Angiography-guided DCB treatment for coronary denovo lesions in patients with high bleeding risk.

Detailed Description

This is a prospective, multicenter, randomized controlled trial that aims to enroll 260 patients with high bleeding risk. All patients with coronary denovo lesions suitable for DCB treatment will undergo 1:1 randomization to either IVUS guidance or Angiography guidance using the Central Randomization System. All subjects will be screened according to the predefined inclusion and exclusion criteria per protocol. Data and images will be collected during the index procedure, and at the predefined 7-month coronary angiography follow-up visit.

Registry
clinicaltrials.gov
Start Date
February 3, 2020
End Date
December 30, 2023
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Junjie Zhang

Vice chief of the department of cardiology

Nanjing First Hospital, Nanjing Medical University

Eligibility Criteria

Inclusion Criteria

  • De novo lesions, suitable for DCB treatment.
  • Patients with high bleeding risk.

Exclusion Criteria

  • Target lesion length \> 15mm.
  • Severe calcified lesions.
  • Left main disease.
  • Ostial lesions.
  • Three-vessel disease.
  • Acute myocardial infarction within 48 hours.
  • Target vessel received stent implantation.
  • Hemodynamic instability.

Outcomes

Primary Outcomes

late lumen loss (LLL) at 7 months after procedure

Time Frame: 7 months

LLL is defined as the difference between postprocedural minimal lumen diameter (MLD) minus MLD at the time of angiographic follow-up

Secondary Outcomes

  • Target vessel failure (TVF) at 6 months(6 months)
  • bleeding at 6 months(6 months)

Study Sites (1)

Loading locations...

Similar Trials